



01-12-04

Please type a plus sign inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)		Application Number	10/624,670
		Filing Date	July 21, 2003
		First Named Inventor	LI, YUANHAO
		Group Art Unit	1645
		Examiner Name	
Total Number of Pages in This Submission	6	Attorney Docket Number	CELL-024
<b>ENCLOSURES (check all that apply)</b>			
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group	
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences	
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)	
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information	
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter	
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation	<input checked="" type="checkbox"/> Other Enclosure(s) SB08A (4pgs.) 47 References	
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Change of Correspondence Address		
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Terminal Disclaimer		
<input type="checkbox"/> Certified Copy of Priority Documents	<input type="checkbox"/> Request for Refund		
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	<input type="checkbox"/> CD, Number of CD(s)		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	Remarks		
<b>SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT</b>			
Signing Attorney/Agent (Reg. No.)	PAMELA J. SHERWOOD, 36.677 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	January 8, 2004		

EXPRESS MAIL LABEL NO. EV333 998 429US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 333 998 429US

<b>INFORMATION DISCLOSURE STATEMENT</b>  Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	CELL-024
	First Named Inventor	LI, YUANHAO
	Application Number	10/624,670
	Confirmation No.	1674
	Filing Date	July 21, 2003
	Group Art Unit	1645
	Examiner Name	
	Title: "METASTATIC COLON CANCER SPECIFIC PROMOTER AND USES THEREOF"	

Sir:


This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.


As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. CELL-024 may be charged thereon.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: January 8, 2004

By:   
Pamela J. Sherwood  
Registration No. 36,677

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>	
		Application Number	10/624,670
		Filing Date	July 21, 2003
		First Named Inventor	LI, YUANHAO
		Art Unit	1645
Examiner Name			
Sheet 1 of 4	Attorney Docket Number	CELL-024	

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				
		5,112,767		05-12-1992	Roy-Burman et al.	
		5,677,178		10-14-1997	McCormick	
		5,698,443		12-16-1997	Henderson et al.	
		5,747,469		05-05-1998	Roth et al.	
		5,801,029		11-01-1998	McCormick	
		5,871,726		02-16-1999	Henderson et al.	
		5,998,205		12-07-1999	Hallenbeck et al.	
		6,432,700		08-13-2002	Henderson et al.	
		6,436,394		08-20-2002	Henderson et al.	
		6,495,130		12-17-2002	Henderson et al.	
		6,551,587		04-22-2003	Hallenbeck et al.	
		6,585,968		07-01-2003	Little, et al.	
		6,638,762		10-28-2003	Chang et al.	
		2003104624		06-05-2003	Hallenbeck et al.	
		2003118570		06-26-2003	Hallenbeck et al.	
		2003129175		07-10-2003	Hallenbeck et al.	
		2003157688		08-21-2003	Hallenbeck et al.	
		20010053768		12-20-2001	Gregory	


FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> –Number <sup>4</sup> –Kind Code <sup>5</sup> (if known)				
		WO 02/067861	09-06-2002	Hallenbeck et al.		
		WO 02/068627	09-06-2002	Hallenbeck et al.		
		WO 92/03563	03-05-1992	Glazenburg		
		WO 96/17053	06-06-1996	Hallenbeck et al.		
		WO 96/18418	06-20-1996	Kadden et al.		
		WO 98/29555	07-09-1998	Onyx		
		WO 98/35554	08-20-1998	Canji		
		WO 99/25860	05-27-1999	Hallenbeck et al.		
		WO 99/59604	11-25-1999	Onyx		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitution for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>	
			Application Number	10/624,670
			Filing Date	July 21, 2003
			First Named Inventor	LI, YUANHAO
			Group Art Unit	1645
Examiner Name				
Sheet 2 of 4	Attorney Docket Number	CELL-024		

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ABE et al., "Characterization of Cis-Acting Elements Regulating Transcription of The Human Breast Carcinoma-Associated Antigen (MUC1) Gene", Proc. Natl. Acad. Sci. USA, January 1993; 90:282-286	DF3
		ARMITAGE JO et al., "Emerging Aplications Of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor", Blood, 1998; 92(12): 4491-508. 92(12)	
		BABBISS et al., "Cellular Promoters Incorporated Into The Adenovirus Genome; Effects Of Viral Regulatory Elements On Transcription Rates and Cell Specificity Of Albumin And Beta-Globin Promoters", 1986; 3798-806	
		BERKNER, K.L., et al., "Biotechniques", Eaton Publishing, London, UK 1988	
		BRISTOL et al., "In Vitro And In Vivo Activities Of An Oncolytic Adenoviral Vector Desined to Express GM-CSF", 2003; 7(6):755-64	
		CHANG, J. et al., "The Epithelial Mucin, MUC1, Is Expressed On Resting T Lymphocytes And Can function As a Negative Regulator of T Cell Activation", Cell Immunology, May 2000; 1; 201(2) 83-88,	
		CHEN Y et al., "CV706,a Prostate Cancer-Specific Adenovirus variant, In Combination With Radiotherapy Produces Synergistic Antitumor Efficacy Without Increasing Toxicity", Cancer Res. 2001; 61(14):5453-60	
		CLEUTJENS et al., "A 6-KB Promoter Fragment Mimics In Transgenic Mice The Prostate-Specific And Androgen-Regulated Expression Of The Endogenous Prostate-Specific Antigen Gene In Humans", August 1997; 11(9): 1256-65	
		FREIDMAN et al. "Cellular Promoters Incorporated Into The Adenovirus Genome; Cell Specificity Of Albumin And Immunoglobulin Expression", Molecular and Cellular Biology, 1986; 6(11) 3791-3797	
		FREIDMAN, J.M. et al., "Adenoviral Vectors And Liver Specific Gene Control", Transcriptional Control Mechanisms, 1987; 421-435	
		FURUKAWA, K. , et al., "Effect Of Virus-Modified Tumor cell Extracts, Autologous Mononuclear cell Infusions And Interleukin-2 On Oncolytic Activity Of Effector Cells Of Patients With Advanced Ovarian Cancer", Cancer Immunol. 1989; 30:126-132	
		GROOTECLAES, et al., "The 6-Kilobase C-erb B2 Promoter Contains Positive and Negative Regulatory Elements Functional In Human Mammary Cell Lines", Cancer Res., August 1994; 54:4193-4199	
		HALLENBECK, P.L., et al., "A Novel Tumor-Specific Replication-Restricted Adenoviral Vector For Gene Therapy Of Hepatocellular Carcinoma", Human Gene Therapy, 1999; 10:1721-1733	
		Henderson, D.R. et al., "Attenuated Replication Competent Adenovirus For Prostate Cancer: CV706 And CV787 Replication-Competent Viruses For Cancer Therapy", Monographs In Virology, Eds. Driever PH& Rabkin SD (Basel, Karger), 2001; 57-80, Vol. 22	
		HERMAN, Trends In Biochemical Sciences, 1989; 14(6): 219-222	
		JACKSON et al., "Internal Initiation Of Ranslation In Eukaryotes", The Picornavirus Paradigm And Beyond; 1995; 1(10): 985-1000	
		KENNEY, S., et al., "Viruses As Oncolytic Agents: A New Age For 'Therapeutic' Viruses", J. National Cancer Institute, August 1994; 86:1185-1186	



Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/624,670	
			Filing Date	July 21, 2003	
			First Named Inventor	LI, YUANHAO	
			Group Art Unit	1645	
Examiner Name					
Sheet	3	of	4	Attorney Docket Number	CELL-024

	KOVARIK, et al., "Analysis Of The Tissue-Specific Promoter of The MUC1 Gene", J. Biol. Chem., May 1993; 268:9917-9926	
	LI, Y. et al., "A Hepatocellular Carcinoma-Specific Adenovirus Variant, CV890, Eliminates Distant Human Liver Tumors In Combination With Doxorubicin", Cancer Research, 2001; 64:28-6436, Vol. 61, No.17	
	LIN et al., "A Tissue-Specific Promoter That Can Drive A Foreign Gene To Express In The Suprabasal Urothelial Cells Of Transgenic Mice", Proc National Academy Science USA 1995; 92:679-683	
	MACH N. et al., "Cytokine-Secreting tumor Cell Vaccines", Curr Opinion Immunol. 2000; 12(5): 571-5	
	MATTER et al., "Role of PRL-3, A Human Muscle-Specific Tyrosine Phosphatase, In Angiotensin-II Signaling", Biochem Biophys Res Communication 2001; 283(5): 1061-8	
	MAX-AUDIT, et al., "Transcriptional Regulation Of The Pyruvate Kinase Erythroid-Specific Promoter Isolated From A Patient With Prostate Cancer", J. Biol. Chem., March 1993; 268:5431-5437	
	MILLER, et al., "Progress In Transcriptionally Targeted and Regulated Vectors For Genetic Therapy", Human Gene Therapy, May 1, 1997; 8:803-815	
	NEAGOE, G., et al., "Methods Of Active Immunotherapy And Viral Oncolysis In Some Forms Of Cancer", Rev. Roum. Med. -Med. Int. 1986; 30:126-132	
	PANG, et al., "Prostate Tissue Specificity Of The Prostate-Specific Antigen Promoter Isolated From A Patient With Prostate Cancer", Human Gene Therapy, November 1995; 6:1414-1426	
	PARDOLL, "Paracrine Cytokine Adjuvants In Cancer Immunotherapy", Annu Rev Immunol. 1995; 13:399-415	
	REIGMAN et al., "The Promoter Of The Prostate-Specific Antigen Gene Contains A Functional Androgen Responsive Element", 1991; 5(12) 1921-1930	
	SAHA et al., "A Phosphatase Associated With Metastasis of Colorectal Cancer", 2001; Science. 294 (5545): 1343-6	
	SHOHAM, J., et al., "Augmentation Of Tumor Cell Immunogenicity By Viruses-An Approach to Specific Immunotherapy Of Cancer", Nat. Immun. , Cell Growth Regul., 1990; 9:165-172	
	SINKOVICS, J.G., "Viral Oncolysates As Human Tumor Vaccines", Inter, Rev. Immunol. 1991; 7:259-287	
	TANEJA, S.S., et al., "In Vitro Target Specific Gene therapy For Prostate Cancer Utilizing A Prostate Specific Antigen Promoter-Driven Adenoviral 1 Vector", Proc. Am. Assn. Cancer Research, 1994; 35:375, Abstract No. 2236, American Association For Cancer Research, Washington, DC	
	YOHN, D.S., et al., "Oncolytic Potentials Of Nonhuman Viruses For Human Cancer. II Effects of Five Viruses on Heterotransplantable Human Tumors", J. Natl. Cancer, Institute, 1968; 41:523-529	
	YU, DC et al., "Selectively Replication Oncolyti Adenoviruses As Cancer Therapeutics", Current Opinion In Molecular Therapeutics, 2002; 4(5) 435-443	
	YU, DC et al., "Antitumor Synergy Of CV787, A Prostate Cancer-Specific Adenovirus, and Paclitaxel And Docetaxel", 2001; 517-525; Vol. 22	
	YU, DC et al., "The Addition Of Adenovirus Type 5 Region E3 Enables Calydon Virus 787 To Eliminate Distant Prostate Tumor Xenografts", Cancer Research, 1999; 4200-4203; Vol. 59 No.17	



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>		<b>Complete if Known</b>			
		Application Number	10/624,670		
		Filing Date	July 21, 2003		
		First Named Inventor	LI, YUANHAO		
		Group Art Unit	1645		
		Examiner Name			
Sheet	4	of	4	Attorney Docket Number	CELL-024

		YU, DC et al., "Identification Of The Transcriptional Regulatory Sequences Of Human Kallikrein 2 And Their Use In The Construction Of Calydon Virus 764, An Attenuated Replication Competent Adenovirus For Prostate Cancer Therapy", Cancer Research, 1999; 1498-1504; Vol.59 No.7	
		ZENG et al., "Prenylation-Dependent Association Of Protein-Tyrosine Phosphatases PRL-1, -2, and -3 With The Plasma Membrane And The Early Endosome", J. Biol Chem. 2000; 275(28):21444-52	
		ZHANG J et al., "Identification Of Human Uroplakin II Promoter And Its Use In The Construction Of CG8840, An Urothelium-Specific Adenovirus Variant That Eliminates Established Bladder Tumors In Combination With Docetaxel", Cancer Research, 2002; 3743-3750; Vol. 62	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.